Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

T. Meyer; R. Finn; M. Kudo; Y. Kang; C. Yen; P. Galle; J. Llovet; E. Assenat; G. Brandi; K. Motomura; T. Okusaka; R. Hubner; M. Karwal; A. Baron; M. Ikeda; K. Liang; C. Wang; R. Widau; W. Schelman; A. Zhu

doi:10.1093/annonc/mdz154.020

Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

T. Meyer
, R. Finn
, M. Kudo
, Y. Kang
, C. Yen
, P. Galle
, J. Llovet
, E. Assenat
, G. Brandi
, K. Motomura
, T. Okusaka
, R. Hubner
, M. Karwal
, A. Baron
, M. Ikeda
, K. Liang
, C. Wang
, R. Widau
, W. Schelman
, A. Zhu

Department of Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	iv133
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	30
DOIs	https://doi.org/10.1093/annonc/mdz154.020
Publication status	Published - 2019 Jul 1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Hematology
Oncology

Access to Document

10.1093/annonc/mdz154.020

Cite this

Meyer, T., Finn, R., Kudo, M., Kang, Y., Yen, C., Galle, P., Llovet, J., Assenat, E., Brandi, G., Motomura, K., Okusaka, T., Hubner, R., Karwal, M., Baron, A., Ikeda, M., Liang, K., Wang, C., Widau, R., Schelman, W., & Zhu, A. (2019). Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). Annals of oncology : official journal of the European Society for Medical Oncology, 30, iv133. https://doi.org/10.1093/annonc/mdz154.020

Meyer, T. ; Finn, R. ; Kudo, M. et al. / Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib : outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). In: Annals of oncology : official journal of the European Society for Medical Oncology. 2019 ; Vol. 30. pp. iv133.

@article{3517581250db446d9888dc5a4f386128,

title = "Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)",

author = "T. Meyer and R. Finn and M. Kudo and Y. Kang and C. Yen and P. Galle and J. Llovet and E. Assenat and G. Brandi and K. Motomura and T. Okusaka and R. Hubner and M. Karwal and A. Baron and M. Ikeda and K. Liang and C. Wang and R. Widau and W. Schelman and A. Zhu",

year = "2019",

month = jul,

day = "1",

doi = "10.1093/annonc/mdz154.020",

language = "English",

volume = "30",

pages = "iv133",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Elsevier Limited",

}

Meyer, T, Finn, R, Kudo, M, Kang, Y, Yen, C, Galle, P, Llovet, J, Assenat, E, Brandi, G, Motomura, K, Okusaka, T, Hubner, R, Karwal, M, Baron, A, Ikeda, M, Liang, K, Wang, C, Widau, R, Schelman, W & Zhu, A 2019, 'Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 30, pp. iv133. https://doi.org/10.1093/annonc/mdz154.020

Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). / Meyer, T.; Finn, R.; Kudo, M. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 30, 01.07.2019, p. iv133.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib

T2 - outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

AU - Meyer, T.

AU - Finn, R.

AU - Kudo, M.

AU - Kang, Y.

AU - Yen, C.

AU - Galle, P.

AU - Llovet, J.

AU - Assenat, E.

AU - Brandi, G.

AU - Motomura, K.

AU - Okusaka, T.

AU - Hubner, R.

AU - Karwal, M.

AU - Baron, A.

AU - Ikeda, M.

AU - Liang, K.

AU - Wang, C.

AU - Widau, R.

AU - Schelman, W.

AU - Zhu, A.

PY - 2019/7/1

Y1 - 2019/7/1

UR - https://www.scopus.com/pages/publications/85079423446

UR - http://www.scopus.com/inward/citedby.url?scp=85079423446&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz154.020

DO - 10.1093/annonc/mdz154.020

M3 - Article

C2 - 32085038

SN - 0923-7534

VL - 30

SP - iv133

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Meyer T, Finn R, Kudo M, Kang Y, Yen C, Galle P et al. Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Jul 1;30:iv133. doi: 10.1093/annonc/mdz154.020

Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this